World Markets Simplified

A 22-year-old B Tech student from the Indian Institute of Technology (IIT)-Delhi was arrested in Hyderabad by the cyber crime wing of the CID for allegedly posting obscene photographs of a girl from IIT-Kanpur on a public blog.

The cyber police seized a mobile phone and a computer from the accused, Surender.

The superintendent of police, cyber crime, U Rammohan Rao said they arrested Surender by tracking the Internet Protocol (IP) address of his computer and calls from his mobile phone.

Surender and the girl both hail from Mahabubabad in Warangal district.

Surender came into contact with the girl when she approached him for guidance for IIT Joint Entrance Examinations (JEE). According to police, Surender got attracted towards the girl and tried to take undue advantage of their closeness. When she resisted his advances, he started harassing her through phone calls, SMSs and emails.

A police source said Surender confessed that he bore a grudge against the girl for refusing to marry him.

In order to harass her and her family members, he created a fake profile in the name the girl's sister on a public blog and chatted with people asking them to call her by giving the number of the girl's mother.

The police initiated action following a complaint by the girl's father that Surender was harassing and blackmailing his daughter and other family members.

Earlier, three cases were registered in Kanpur and Mahabubabad against the accused for harassing the girl and trying to forcibly marry her in the Arya Samaj office in Kanpur," Rammohan said.

Major global companies consider India their third most favoured destination after China and the United States, a UN report said on Thursday, and investment inflows could increase by more than 20 per cent both this year and next.

Foreign direct investment (FDI) flows into India leapt 30 per cent to nearly $32 billion in 2011, though held back by slow pace of reforms, it still remains a long way down the league table of FDI recipients.

China drew $124 billion last year, while Brazil attracted nearly $67 billion and Russia $53 billion.

"The FDI inflows into India can go up by 20-25 per cent this year and by about 20 per cent next year, if the present trend continues," said Nagesh Kumar, Chief Economist, United Nations Economic and Social Commission for Asia and the Pacific, while releasing the UNCTAD's World Investment Report 2012.

Some 179 global companies - from the manufacturing, services and primary sectors - were surveyed between February and May, on their favoured investment destinations for 2012 to 2014.

Kumar said FDI growth seems to be keeping its momentum in 2012, referring to furniture maker IKEA and Coca Cola's recent announcements to pump nearly $5 billion combined into India over the long term.

Though India's economic growth slowed to 5.3 per cent in the March quarter, its slowest in nine years, its trends still compared favorably, Kumar said.

"Compared to many other places, India is doing better in terms of growth," he said, adding global investors were looking at the long term prospects and wide market in Asia's third largest economy.

The report said worldwide FDI flows exceeded the pre-financial crisis average in 2011, reaching around $1.5 trillion, despite turmoil in the global economy, and is projected around $1.6 trillion this year.

Global companies are sitting on hefty cash reserves and waiting for the euro zone situation to stabilise before investing, he said.

Earlier this year India allowed full foreign ownership of single brand retailers, although late last year it backtracked on a plan to allow in foreign supermarkets.

Many investors are hoping it revives that plan soon, after Prime Minister Manmohan Singh recently took over the finance portfolio and talked about the need to address problems in the insurance and mutual fund industries, as well as taxation.

Kumar said corporate investors look at long term prospects and recent controversies over retroactive tax proposals broadly aimed at taxing companies like Vodafone, or proposed general anti-tax avoidance rules (GAAR) would not hurt India's prospects as an investment destination.

Acrtess Scarlett Johansson is reportedly being paid 13 million pound to act in 'Avengers 2' the most an actress has ever been paid for a movie. The 27-year-old, who plays the Black Widow in the superhero film, tops superstar Angelina Jolie's 12.2 million pound fees for 'The Tourist', reported Sun Online.

Movie bosses want Johansson for the sequel after 'The Avengers' grossed 936 million pound, the third highest in history.

"Scarlett is the hottest star in Hollywood and her inclusion in the sequel is a must. Producers think that as the only lead woman in the film male fans have found her a key ingredient both for sex and story appeal. She is loved by critics too. This says, 'We value you'. Everyone is confident she'll sign and be ready for 2013 filming," a source said.

Actors Robert Downey Jr, Chris Hemsworth and Jeremy Renner are also to get 50 per cent pay rises.

Soon the popular social networking site Facebook will become a recruiter, as per knowledgeable sources, by launching its own job board after teaming with existing job-posting companies, the sources said.

Citing anonymous sources, media reports said that BranchOut, Jobvite and Work4Labs will be at least three of the companies that will pair with the platform.

With the rise of LinkedIn - and its aggressive moves into social-networking functionality - having Facebook enter the fray is an obvious play for them.

Whether or not the job posts will display in the news feed is unclear.

Many bigger companies have career recruitment presences on Facebook already, but a centralised engine behind job postings and searches would feed the engagement metrics.

According to recent estimates, the job-posting market is worth about USD 4.3 billion and everyone would like to have a piece of it.

Last October, the social networking site initiated its move towards becoming a source for job hunters by teaming up with the US Department of Labor and three employment-related agencies in an attempt to decrease the country's 9.1 per cent unemployment rate using social media a project that may eventually include a Facebook job posting system.

This partnership started a new era of formal job hunting content on Facebook which some recruiters already prefer over LinkedIn for the first time.

As part of the initiative, Facebook launched a "Social Jobs" portal that makes easily accessible educational content and tools from its partners at the Department of Labor, National Association of Colleges and Employers, Direct Employers Association, and the National Association of State Workforce Agencies.

It plans to promote this page in the 10 states with the highest unemployment rates and Puerto Rico.

The most interesting aspect of the new partnership, however, is a plan to inch Facebook into job listings territory.

Facebook's statement announcing the partnership mentioned "systems where new job postings can be delivered virally through the Facebook site at no charge."

What shape such a job posting system would take, and whether Facebook has any solid plans beyond research to pursue one, are still not clear.

A job board that lives on Facebook could put the social network in direct competition with sites like LinkedIn and Monster.com.

( IANS )

Facebook Funds Asia Internet Cable Project
Facebook is investing in undersea fiber-optic Internet cabling that will connect much of Asia with the Internet, and by extension, the rest of North America. The social network has contributed an undisclosed amount to the $450 million in total funding the Asia Pacific Gateway has received, the BBC reports.

The Asia Pacific Gateway will bring Internet access to a large sectoin of Southeast Asia, running 6,200 miles from Malaysia to Japan. The project is also backed by China’s leading telecoms China Unicom and China Telecom.

• Forest Laboratories, Inc. (FRX) Slammed With $100 Million Gender Bias Suit More...

Penny stock Chelsea Therapeutics International Ltd. ( NASDAQ: CHTP ) stock gained more than 25 % and trading above $1.15 with above average volumes. There was not any announcements regarding any development. Investors might be accumulating the stock for future positive developments from the company and value unlocking. One should watch the stock for possible break out.
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson’s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome. In addition, the Company is developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and is exploring potential applications in multiple other autoimmune disorders.

XOMA corporation ( NASDAQ: XOMA ), stock of the company spiked more than 15 % suddenly, traders might keep an eye on stock as there might be a big news announcement from the company.
 Company has announced an enrollment for Phase II/Phase III trials of gevokizumab to treat interleukin-1 beta-mediated inflammatory diseases

Press release read below

It has opened enrollment in two clinical trials to determine gevokizumab's potential to treat interleukin-1 beta-mediated inflammatory diseases. The first trial is XOMA's global Phase 3 study investigating the ability of gevokizumab to reduce the signs and symptoms, including vitreous haze, in patients with non-infectious uveitis (NIU) involving the intermediate and/or posterior segment of the eye. The second trial is a Phase 2 study to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with erosive osteoarthritis of the hand. Patients currently are being screened in both trials.

In this study, titled A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis, the Company intends to enroll patients with active non-infectious intermediate, posterior, or pan-uveitis with a vitreous haze score equal to or greater than 2+ on the Standardization of Uveitis Nomenclature (SUN) / National Eye Institute (NEI) scale in at least one eye. They will be randomized to receive either one of two doses of gevokizumab or placebo. The study's primary endpoint is the proportion of patients demonstrating a significant reduction in vitreous haze score on Day 56. The study also will assess the effect of gevokizumab on additional endpoints, including response rates at other time points and changes from baseline in visual acuity.

Paul Rubin, M.D., XOMA's Senior Vice President of Research and Development and Chief Medical Officer, stated, "As preclinical and clinical data have shown that IL-1 beta is an important contributor to the inflammation seen in uveitis, we believe gevokizumab's ability to potently inhibit IL-1 beta signaling could be relevant in controlling this inflammation, as well as the inflammation associated with other conditions. Because of this, we established a proof-of-concept program in November 2011 to lead us to additional indications for this antibody. Included in this program is the ongoing trial in moderate to severe acne vulgaris from which we anticipate top-line data by year end. Today, we opened enrollment in the second POC indication, erosive osteoarthritis of the hand, which we believe will complete enrollment sometime around the end of 2012."

XOMA's Phase 2 proof-of-concept study of gevokizumab in active inflammatory, erosive osteoarthritis of the hand is designed to enroll approximately 90 patients who will be randomized to receive gevokizumab or placebo. The study is designed and powered to detect a significant improvement from baseline versus placebo in the mean Australian/Canadian Hand Osteoarthritis Index (AUSCAN™) pain score in the target hand at three months. The study also will capture multiple outcome measures including pain, stiffness, physical function, radiographic and MRI changes, as well as changes in C-reactive protein and concomitant acetaminophen use.

About XOMA corporation:


XOMA Corporation (XOMA), formerly XOMA Ltd., discovers and develops antibody-based therapeutics. XOMA’s drug candidate gevokizumab is an antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). Its XOMA 3AB is a biodefense anti-botulism product candidate consists of a combination of antibodies, was developed through funding from the National Institute of Allergy and Infectious Diseases (NIAID) of the United Sates National Institutes of Health (NIH). In June 2011, it discovery of two classes of human monoclonal antibodies, XOMA Metabolic Activating and Sensitizing (XMetA and XMetS), On January 17, 2012, it announced that it had acquired the United Sates rights to the perindopril franchise from Servier. The agreement includes ACEON, a marketed angiotensin converting enzyme (ACE) inhibitor, and a portfolio of three fixed-dose combination product candidates where perindopril is combined with another active ingredient(s), such as a calcium channel blocker.

Rexahn Pharmaceuticals, Inc ( AMEX: RNN ) Submits an Investigational New Drug Application to the FDA for First-in-Class p68 Helicase Inhibitor, RX-5902. Stock jumped more than 15 % and trading at $0.63. It has gained more than 80% in last three trading session. There was no official announcements regarding any developments from company. Stock might see more upside in near future, Traders might track the penny stock which might explode soon.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors. RX-5902 is a first-in-class small molecule that inhibits the phosphorylated p68 RNA helicase, a protein that plays a key role in cancer growth, progression and metastasis. The phosphorylated form of p68 RNA helicase is only present in cancer cells and is absent in normal cells.

“RX-5902 is an exciting first-in-class p68 RNA helicase inhibitor that has considerable commercial potential,” said Rick Soni, President of Rexahn. “Pre-clinical studies have shown that RX-5902 exhibits very potent anti-tumor activity in various cancers including melanoma, renal, ovarian and pancreatic. Additional studies suggest that RX-5902 is effective in drug-resistant cancer cells and is synergistic when combined with current cancer drugs.” Rexahn Pharmaceuticals, Inc. (Rexahn) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Rexahn’s pipeline features three drug candidates in Phase II clinical trials and seven or more other drug candidates in pre-clinical development. Rexahn has three clinical stage drug candidates: Archexin, Serdaxin, and Zoraxel. Archexin, is a inhibitor of the protein kinase Akt. Archexin is developed for five cancer indications (renal cell carcinoma (RCC), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer). Its products in the pre-clinical pipeline include RX-1792, RX-5902, RX-3117, RX-8243, RX-0201, RX-0047, RX-21101 and RX-21202